Search

Dawah Pharmaceuticals Updates | December 2019

  1. Our contracted CMO has successfully completed the scale-up batch on the product. The three exhibit batches are scheduled for the next 3 weeks. This means that we are on target to file our ANDA with the FDA by 2Q2020, which aligns us with our projected timeline to market!

  2. Our other contracted CMO had a recent successful US-FDA inspection which will lead to a smooth approval of our other manufactured drug. They have met the US statutory required regulations.

  3. The FDA dossier for submission is in the preparation process for our licensed drug and on its way to being complete. After review from notable regulatory consulting firms that represent big pharma organizations, we have been given the thumbs up that our submission will most likely be approved by the FDA.

48 views0 comments

Recent Posts

See All

To our investors: The current international social and financial impact of COVID-19 has not affected the progress of Dawah Pharma's entry to market. If anything, it has expedited the FDA approval proc

New York, NY – The global pharmaceutical market is estimated to be valued at $1.5 trillion by 2020 and witnessing a growth of 4-5%. In the last 3 decades, the pharmaceutical market witnessed a shift f